165 related articles for article (PubMed ID: 31420092)
1. Interleukin-33/ST2 Signaling Promotes Hepatocellular Carcinoma Cell Stemness Expansion Through Activating c-Jun N-terminal Kinase Pathway.
Zhao R; Yu Z; Li M; Zhou Y
Am J Med Sci; 2019 Oct; 358(4):279-288. PubMed ID: 31420092
[TBL] [Abstract][Full Text] [Related]
2. The Interleukin-33/ST2 axis promotes glioma mesenchymal transition, stemness and TMZ resistance via JNK activation.
Lin L; Li Y; Liu M; Li Q; Liu Q; Li R
Aging (Albany NY); 2020 Jan; 12(2):1685-1703. PubMed ID: 32003751
[TBL] [Abstract][Full Text] [Related]
3. IL33 Promotes Colon Cancer Cell Stemness via JNK Activation and Macrophage Recruitment.
Fang M; Li Y; Huang K; Qi S; Zhang J; Zgodzinski W; Majewski M; Wallner G; Gozdz S; Macek P; Kowalik A; Pasiarski M; Grywalska E; Vatan L; Nagarsheth N; Li W; Zhao L; Kryczek I; Wang G; Wang Z; Zou W; Wang L
Cancer Res; 2017 May; 77(10):2735-2745. PubMed ID: 28249897
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-33 Predicts Poor Prognosis and Promotes Renal Cell Carcinoma Cell Growth Through its Receptor ST2 and the JNK Signaling Pathway.
Wu CW; Wu YG; Cheng C; Hong ZD; Shi ZM; Lin SQ; Li J; He XY; Zhu AY
Cell Physiol Biochem; 2018; 47(1):191-200. PubMed ID: 29763892
[TBL] [Abstract][Full Text] [Related]
5. IL33/ST2 contributes to airway remodeling via p-JNK MAPK/STAT3 signaling pathway in OVA-induced allergic airway inflammation in mice.
Zhang Y; Li S; Huang S; Cao L; Liu T; Zhao J; Wu J; Wang J; Cao L; Xu J; Dong L
Exp Lung Res; 2019; 45(3-4):65-75. PubMed ID: 31112061
[No Abstract] [Full Text] [Related]
6.
Pan X; Li M; Huang L; Mo D; Liang Y; Huang Z; Zhu B; Fang M
Biomed Res Int; 2020; 2020():2918517. PubMed ID: 33062675
[TBL] [Abstract][Full Text] [Related]
7. Genetic variants in IL-33/ST2 pathway with the susceptibility to hepatocellular carcinoma in a Chinese population.
Wei ZH; Li YY; Huang SQ; Tan ZQ
Cytokine; 2019 Jun; 118():124-129. PubMed ID: 29656959
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity.
Kim JY; Lim SC; Kim G; Yun HJ; Ahn SG; Choi HS
Oncogene; 2015 Sep; 34(38):4928-38. PubMed ID: 25531326
[TBL] [Abstract][Full Text] [Related]
9. ERK pathway activation contributes to the tumor-promoting effects of hepatic stellate cells in hepatocellular carcinoma.
Xie YX; Liao R; Pan L; Du CY
Immunol Lett; 2017 Aug; 188():116-123. PubMed ID: 28668554
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of MKK7-JNK by the TOR signaling pathway regulator-like protein contributes to resistance of HCC cells to TRAIL-induced apoptosis.
Song IS; Jun SY; Na HJ; Kim HT; Jung SY; Ha GH; Park YH; Long LZ; Yu DY; Kim JM; Kim JH; Ko JH; Kim CH; Kim NS
Gastroenterology; 2012 Nov; 143(5):1341-1351. PubMed ID: 22841785
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-17A inhibits cell autophagy under starvation and promotes cell migration via TAB2/TAB3-p38 mitogen-activated protein kinase pathways in hepatocellular carcinoma.
Zhou Y; Wu PW; Yuan XW; Li J; Shi XL
Eur Rev Med Pharmacol Sci; 2016; 20(2):250-63. PubMed ID: 26875893
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 33/ST2 Axis Components Are Associated to Desmoplasia, a Metastasis-Related Factor in Colorectal Cancer.
Landskron G; De la Fuente López M; Dubois-Camacho K; Díaz-Jiménez D; Orellana-Serradell O; Romero D; Sepúlveda SA; Salazar C; Parada-Venegas D; Quera R; Simian D; González MJ; López-Köstner F; Kronberg U; Abedrapo M; Gallegos I; Contreras HR; Peña C; Díaz-Araya G; Roa JC; Hermoso MA
Front Immunol; 2019; 10():1394. PubMed ID: 31281317
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-1β/Iinterleukin-1 receptor-associated kinase 1 inflammatory signaling contributes to persistent Gankyrin activation during hepatocarcinogenesis.
Su B; Luo T; Zhu J; Fu J; Zhao X; Chen L; Zhang H; Ren Y; Yu L; Yang X; Wu M; Feng G; Li S; Chen Y; Wang H
Hepatology; 2015 Feb; 61(2):585-97. PubMed ID: 25294684
[TBL] [Abstract][Full Text] [Related]
14. Secretory Stanniocalcin 1 promotes metastasis of hepatocellular carcinoma through activation of JNK signaling pathway.
Chan KK; Leung CO; Wong CC; Ho DW; Chok KS; Lai CL; Ng IO; Lo RC
Cancer Lett; 2017 Sep; 403():330-338. PubMed ID: 28688970
[TBL] [Abstract][Full Text] [Related]
15. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma.
Saxena NK; Fu PP; Nagalingam A; Wang J; Handy J; Cohen C; Tighiouart M; Sharma D; Anania FA
Gastroenterology; 2010 Nov; 139(5):1762-73, 1773.e1-5. PubMed ID: 20637208
[TBL] [Abstract][Full Text] [Related]
16. Receptor for activated C kinase 1 promotes hepatocellular carcinoma growth by enhancing mitogen-activated protein kinase kinase 7 activity.
Guo Y; Wang W; Wang J; Feng J; Wang Q; Jin J; Lv M; Li X; Li Y; Ma Y; Shen B; Zhang J
Hepatology; 2013 Jan; 57(1):140-51. PubMed ID: 22903704
[TBL] [Abstract][Full Text] [Related]
17. P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation.
Ching YP; Leong VY; Lee MF; Xu HT; Jin DY; Ng IO
Cancer Res; 2007 Apr; 67(8):3601-8. PubMed ID: 17440071
[TBL] [Abstract][Full Text] [Related]
18. Decrease of MLK4 prevents hepatocellular carcinoma (HCC) through reducing metastasis and inducing apoptosis regulated by ROS/MAPKs signaling.
Li Y; Zuo H; Wang H; Hu A
Biomed Pharmacother; 2019 Aug; 116():108749. PubMed ID: 31071576
[TBL] [Abstract][Full Text] [Related]
19. ST2 Signaling in the Tumor Microenvironment.
Chang CP; Hu MH; Hsiao YP; Wang YC
Adv Exp Med Biol; 2020; 1240():83-93. PubMed ID: 32060890
[TBL] [Abstract][Full Text] [Related]
20. c-Jun NH2-terminal kinase pathway is involved in constitutive matrix metalloproteinase-1 expression in a hepatocellular carcinoma-derived cell line.
Sugioka Y; Watanabe T; Inagaki Y; Kushida M; Niioka M; Endo H; Higashiyama R; Okazaki I
Int J Cancer; 2004 May; 109(6):867-74. PubMed ID: 15027120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
